pharmaphorum
FEBRUARY 25, 2024
Rare Disease Day 2024 is an important opportunity to raise awareness about rare diseases and the need for research, diagnosis, and treatment options like orphan drugs. Learn the significance of shining a light on rare diseases.
Drug Patent Watch
FEBRUARY 25, 2024
This chart shows the pharmaceutical companies with the most patents in Serbia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is… The post Which pharmaceutical companies have the most drug patents in Serbia? appeared first on DrugPatentWatch - Make Better Decisions.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
FEBRUARY 25, 2024
TevaU and Alvotech claim first US approval for first biosimilar of AbbVie’s high-concentration Humira, which accounts for 88% of brand prescriptions
Outsourcing Pharma
FEBRUARY 25, 2024
Results from a phase 3 trial looking at treatment for primary biliary cholangitis (PBC) are 'genuinely exciting' and supports the potential for seladelpar to raise the bar in treatment of the disease.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
JAMA Internal Medicine
FEBRUARY 25, 2024
This cohort study assesses long-term kidney outcomes among hospitalized patients with COVID-19−associated acute kidney injury.
Drug Patent Watch
FEBRUARY 25, 2024
Annual Drug Patent Expirations for NASCOBAL Nascobal is a drug marketed by Par Pharm and Endo Pharms Inc and is included in two NDAs. It is available from one supplier.… The post New patent expiration for Endo Pharms drug NASCOBAL appeared first on DrugPatentWatch - Make Better Decisions.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Drug Patent Watch
FEBRUARY 25, 2024
Annual Drug Patent Expirations for GRALISE Gralise is a drug marketed by Almatica and is included in one NDA. It is available from one supplier. There is one patent protecting… The post New patent expiration for Almatica drug GRALISE appeared first on DrugPatentWatch - Make Better Decisions.
Pharma in Brief
FEBRUARY 25, 2024
On February 23, 2024, Health Canada published a Notice advising that it was making its review process for generic drug submissions more transparent. Specifically, for generic drug submissions accepted into review on or after April 1, 2024, Health Canada will start disclosing: (i) the year and month that the submission was accepted for review; and (ii) the company sponsoring the generic drug.
JAMA Internal Medicine
FEBRUARY 25, 2024
This JAMA Network Insights reassesses the approach to caring for older adults with diabetes in the context of newly available pharmacologic agents.
Expert insights. Personalized for you.
118 
Let's personalize your content